Axogen Reports Q4 Revenue of $59.9M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy AXGN?
Reports Q4 revenue $59.9M, consensus $59.9M. "2025 was a remarkable year of financial and operational achievement for Axogen, as we attained or progressed every objective expected of our strategic plan. With the FDA's approval of our Biologics License Application for Avance as the only implantable biologic indicated for treatment of peripheral nerve discontinuities, and the continued demonstration of the effectiveness and predictability of our market development strategies, we are confident we have a foundation for future growth and advancement of our mission to make restoration of peripheral function a standard of care," commented Michael Dale, President and CEO of Axogen, Inc. "Importantly for shareholders, we exited 2025 financially stronger and positioned to continue our important work profitably while generating positive cash flow."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXGN
Wall Street analysts forecast AXGN stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.250
Low
39.00
Averages
39.80
High
40.00
Current: 39.250
Low
39.00
Averages
39.80
High
40.00
About AXGN
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Capricorn Fund Managers Acquires Stake in Axogen
- New Investment Insight: Capricorn Fund Managers Ltd initiated a new stake in Axogen by acquiring 687,600 shares in Q1 2026, valued at approximately $22.36 million, indicating confidence in the company despite its decade-long GAAP losses.
- Holding Proportion Analysis: This new position accounts for 3.55% of Capricorn's reportable U.S. equity assets, highlighting Axogen's significance within Capricorn's portfolio and potentially influencing future investment strategies.
- Market Performance Review: As of April 23, 2026, Axogen's shares were priced at $37.41, reflecting a 139.5% increase over the past year, significantly outperforming the S&P 500 by 107.3 percentage points, showcasing market optimism regarding its growth prospects.
- Future Outlook: Axogen anticipates at least an 18% year-over-year revenue increase for 2026 and plans to report its Q1 results on April 28, with management expecting positive free cash flow this year, further enhancing its investment appeal.
See More
Capricorn Fund Increases Stake in Axogen
- New Investment Size: Capricorn Fund acquired 687,600 shares of Axogen in Q1 2026, with an estimated transaction value of $22.36 million, indicating new interest in the company despite its decade-long losses.
- Holding Value Increase: As of March 31, 2026, the value of Axogen's stake rose to $22.78 million, reflecting the impact of both the new purchase and price changes, making it the fund's fourth-largest holding at approximately 3.55% of AUM.
- Market Outlook: Axogen expects its 2026 revenue to increase by at least 18% year-over-year, driven by FDA approval of its Avance product, which may enhance its competitiveness in the biologics market, although it still faces market challenges.
- Investment Risk Warning: While Capricorn's investment in Axogen is noteworthy, analysts point out that the company did not make the list of top investment stocks, suggesting that investors should carefully consider its long-term profitability.
See More
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aiming to enhance the company's leadership in cardiovascular treatment.
- Rich Industry Experience: Dale brings an outstanding record of commercial success in the medical device industry, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide valuable strategic guidance for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim is the first FDA-approved medical device utilizing neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market penetration of this technology, enhancing patient treatment outcomes.
- Global Market Compliance: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will aid CVRx in compliance and expansion in global markets.
See More
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aimed at strengthening the company's leadership in cardiovascular treatment.
- Extensive Industry Experience: Dale brings a proven track record of commercial success in the medical device sector, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide strategic support for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim technology is the first FDA-approved medical device that uses neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market acceptance of this technology, driving company growth in cardiovascular treatment.
- International Certification Advantage: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will further enhance CVRx's competitiveness and compliance in the global market.
See More
Axogen Executive Exercises Stock Options, Sells Shares
- Executive Stock Transaction: Axogen's Chief Innovation Officer Erick Wayne Devinney exercised 17,938 options on March 16, 2026, selling 5,221 shares of common stock for approximately $171,000, indicating active management participation in the market.
- Tax Handling and Liquidity: The transaction involved selling 5,221 shares for liquidity needs while withholding 2,870 shares for tax obligations, reflecting a balance between executive compensation mechanics and tax responsibilities.
- Change in Ownership: Post-transaction, Devinney directly owns 262,781 shares valued at about $8.6 million, indicating continued confidence in the company's future despite the partial sale of shares.
- Company Performance Outlook: Axogen reported $225.21 million in revenue for 2025, a 20.2% year-over-year increase, and anticipates at least 18% growth in 2026, highlighting ongoing growth potential in the surgical sector, prompting investors to focus on improving profitability.
See More
DAFNA Capital Management Reduces AXGN Holdings
- Holding Reduction: DAFNA Capital Management sold 265,456 shares of Axogen in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategic adjustment in their high-risk biotech investment approach.
- Market Value Change: Post-sale, DAFNA's total Axogen holdings decreased to 476,826 shares, valued at $15.61 million at quarter-end, reflecting a $2.36 million decline due to market fluctuations impacting the portfolio.
- Company Background: Axogen specializes in advanced medical devices for peripheral nerve repair and regeneration, achieving approximately 20% revenue growth to $225 million last year, although profitability remains a work in progress amid regulatory cost pressures.
- Market Outlook: The FDA approval of Avance and improved reimbursement dynamics provide Axogen with a clearer path for scaling, and while not included in The Motley Fool's top 10 recommended stocks, its steady growth potential remains noteworthy.
See More
Capricorn Fund Managers Acquires Stake in Axogen
- New Investment Insight: Capricorn Fund Managers Ltd initiated a new stake in Axogen by acquiring 687,600 shares in Q1 2026, valued at approximately $22.36 million, indicating confidence in the company despite its decade-long GAAP losses.
- Holding Proportion Analysis: This new position accounts for 3.55% of Capricorn's reportable U.S. equity assets, highlighting Axogen's significance within Capricorn's portfolio and potentially influencing future investment strategies.
- Market Performance Review: As of April 23, 2026, Axogen's shares were priced at $37.41, reflecting a 139.5% increase over the past year, significantly outperforming the S&P 500 by 107.3 percentage points, showcasing market optimism regarding its growth prospects.
- Future Outlook: Axogen anticipates at least an 18% year-over-year revenue increase for 2026 and plans to report its Q1 results on April 28, with management expecting positive free cash flow this year, further enhancing its investment appeal.
See More
Capricorn Fund Increases Stake in Axogen
- New Investment Size: Capricorn Fund acquired 687,600 shares of Axogen in Q1 2026, with an estimated transaction value of $22.36 million, indicating new interest in the company despite its decade-long losses.
- Holding Value Increase: As of March 31, 2026, the value of Axogen's stake rose to $22.78 million, reflecting the impact of both the new purchase and price changes, making it the fund's fourth-largest holding at approximately 3.55% of AUM.
- Market Outlook: Axogen expects its 2026 revenue to increase by at least 18% year-over-year, driven by FDA approval of its Avance product, which may enhance its competitiveness in the biologics market, although it still faces market challenges.
- Investment Risk Warning: While Capricorn's investment in Axogen is noteworthy, analysts point out that the company did not make the list of top investment stocks, suggesting that investors should carefully consider its long-term profitability.
See More
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aiming to enhance the company's leadership in cardiovascular treatment.
- Rich Industry Experience: Dale brings an outstanding record of commercial success in the medical device industry, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide valuable strategic guidance for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim is the first FDA-approved medical device utilizing neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market penetration of this technology, enhancing patient treatment outcomes.
- Global Market Compliance: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will aid CVRx in compliance and expansion in global markets.
See More
CVRx Nominates Michael Dale to Board of Directors
- New Board Member: CVRx has nominated Michael Dale to its Board of Directors, with the election scheduled for June 1, 2026, aimed at strengthening the company's leadership in cardiovascular treatment.
- Extensive Industry Experience: Dale brings a proven track record of commercial success in the medical device sector, having served as CEO of Axogen and led Abbott's structural heart division for eight years, which is expected to provide strategic support for CVRx's Barostim product promotion.
- Driving Technological Innovation: CVRx's Barostim technology is the first FDA-approved medical device that uses neuromodulation to improve heart failure symptoms, and Dale's addition is anticipated to accelerate market acceptance of this technology, driving company growth in cardiovascular treatment.
- International Certification Advantage: Barostim has received FDA Breakthrough Device designation and complies with EU Medical Device Regulation, and Dale's extensive board experience will further enhance CVRx's competitiveness and compliance in the global market.
See More
Axogen Executive Exercises Stock Options, Sells Shares
- Executive Stock Transaction: Axogen's Chief Innovation Officer Erick Wayne Devinney exercised 17,938 options on March 16, 2026, selling 5,221 shares of common stock for approximately $171,000, indicating active management participation in the market.
- Tax Handling and Liquidity: The transaction involved selling 5,221 shares for liquidity needs while withholding 2,870 shares for tax obligations, reflecting a balance between executive compensation mechanics and tax responsibilities.
- Change in Ownership: Post-transaction, Devinney directly owns 262,781 shares valued at about $8.6 million, indicating continued confidence in the company's future despite the partial sale of shares.
- Company Performance Outlook: Axogen reported $225.21 million in revenue for 2025, a 20.2% year-over-year increase, and anticipates at least 18% growth in 2026, highlighting ongoing growth potential in the surgical sector, prompting investors to focus on improving profitability.
See More
DAFNA Capital Management Reduces AXGN Holdings
- Holding Reduction: DAFNA Capital Management sold 265,456 shares of Axogen in Q4 2025, with an estimated transaction value of $6.53 million, indicating a strategic adjustment in their high-risk biotech investment approach.
- Market Value Change: Post-sale, DAFNA's total Axogen holdings decreased to 476,826 shares, valued at $15.61 million at quarter-end, reflecting a $2.36 million decline due to market fluctuations impacting the portfolio.
- Company Background: Axogen specializes in advanced medical devices for peripheral nerve repair and regeneration, achieving approximately 20% revenue growth to $225 million last year, although profitability remains a work in progress amid regulatory cost pressures.
- Market Outlook: The FDA approval of Avance and improved reimbursement dynamics provide Axogen with a clearer path for scaling, and while not included in The Motley Fool's top 10 recommended stocks, its steady growth potential remains noteworthy.
See More
